Publications and Digital Products

Monitoring the distribution and impact of opioid overdose reversal medications such as naloxone is essential to optimizing overdose prevention strategies and improving public health outcomes. This Statistical Data Profile, the first to use performance data from two SAMHSA grant programs, examines the distribution of FDA-approved opioid overdose reversal medications, including naloxone/Narcan. The Data Profile also presents the training of first responders, community organization staff and other individuals to administer the reversal medications and provide other support services.

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This guide reviews ways that telehealth modalities can be used to provide treatment for serious mental illness and substance use disorders among adults, distills the research into recommendations for practice, and provides examples of how these recommendations can be implemented.

This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation.

This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.

The National report presents indicators as measured through the 2019 National Survey on Drug Use and Health and the National Survey of Substance Abuse Treatment Services. State reports provide a snapshot of substance use and mental health in the United States.